摘要
目的本研究旨在比较国产与进口重组人促卵泡激素(recombinant human follicle stimulating,rhFSH)在辅助生殖技术超排卵治疗中的疗效差异。方法回顾分析了2018年1月—12月在首都医科大学附属北京妇产医院生殖科接受控制性超促排卵后行IVF-ET/ICSI治疗的192个周期的临床资料,根据所用药物不同分为国产组(A组,101个周期)和进口组(B组,91个周期),比较两组患者的一般情况、基础激素水平、用药情况、获卵情况和妊娠结局等是否存在差异。结果两组的一般情况、基础激素水平和基础卵泡数均无显著差异(P>0.05)。两组rhFSH人均用药总量、人均用药天数、加用HMG人数比例、人均用HMG总量、天数,HCG日子宫内膜厚度、LH水平均无明显差异(P>0.05);但是进口组获卵数、HCG日E2、P0水平高于国产组,差异有统计学意义(P<0.05)。两组胚胎种植率、生化妊娠率、临床妊娠率以及流产率均无明显差异(P>0.05);但是,国产组的多胎妊娠率高于进口组,差异有统计学意义(P<0.05)。结论使用相同剂量的rhFSH进行超排卵治疗,国产组可获得与进口组大致相同的胚胎种植率、生化妊娠率、临床妊娠率以及流产率,在不孕患者的辅助生殖治疗中不失为一种好的选择。
Objective:To compare the effect of domestic and imported recombinant human follicle stimulating hormone(rhFSH)in the treatment of controlled ovarian hyperstimulation in assisted reproductive technology.Methods:The clinical data of 192 cycles of IVF-ET/ICSI treatment after controlled ovarian hyperstimulation from January to December 2018 in the Department of Reproductive,Beijing Obstetrics and Gynecology Hospital affiliated to Capital Medical University were retrospectively analyzed.Based on medication,they were divided into Domestic group(group A,101 cycles)and Imported group(group B,91 cycles).The general conditions,basic hormone levels,medication status,egg acquisition status,and pregnancy outcome were compared between the two groups.Results:There was no significant differences in the general condition,baseline hormone levels,and basal follicles between the two groups(P>0.05).And no significant differences in the total dose of rhFSH,the mean days of medication,the proportion of patients with HMG,the total amount of HMG,the mean days of medication of HMG,the endometrial thickness of HCG day,and the LH level(P>0.05).The levels of E2 and P0 in HCG day were higher than those in Domestic group,and the difference was statistically significant(P<0.05).There was no significant difference in implantation rate,biochemical pregnancy rate,clinical pregnancy rate and abortion rate between the two groups(P>0.05).However,the multiple pregnancy rate of Domestic group was higher than that of Imported group,and the difference was statistically significant(P<0.05).Conclusion:Taking the same dose of rhFSH for controlled ovarian hyperstimulation treatment,the implantation rate,biochemical pregnancy rate,clinical pregnancy rate and abortion rate between the Domestic group and the Imported group were similar.In summary,domestic rhFSH is a good choice for assisted reproductive treatment for infertile patients.
作者
袁涛
张巧利
兰永连
刘艳君
李颖
王树玉
刘英
YUAN Tao;ZHANG Qiao-li;LAN Yong-lian;LIU Yan-jun;LI Ying;WANG Shu-yu;LIU Ying(Department of Reproductive Medicine,Beijing Obestetrics and Gynecology Hospital,Capital Medical University,Beijing 100026,China)
出处
《中国优生与遗传杂志》
2019年第10期1254-1256,1269,共4页
Chinese Journal of Birth Health & Heredity
基金
国家自然科学基金(81471520)
北京市自然科学基金(7182054)
北京市卫生系统高层次卫生技术人才培养项目(2014-3-075)
关键词
重组人卵泡刺激素
控制性超排卵
体外受精-胚胎移植
Recombinant human follicle stimulating hormone(rhFSH)
Controlled ovarian hyperstimulation(COH)
In vitro fertilization-embryo transfer(IVF-ET)